

### Investment focus

The fund's aim is to achieve capital growth in the long term. The BB Adamant Emerging Markets Healthcare fund invests in companies that have their registered office or carry out the majority of their economic activity in the healthcare markets of emerging countries. Its investment universe consists of generics producers, pharma and biotechnology companies, medical technology and services firms. Experienced sector specialists focus on profitable companies that have a well-established product portfolio. Investments are made based on fundamental research analysis. Stock selection is exclusively bottom-up, independent of benchmark weightings. The Fund takes ESG factors into consideration while implementing the aforementioned investment objectives.

### Fund facts

NAV	206.39
Volume	EUR 126.2 mn
NAV-calculation	Daily "Forward Pricing"
Cut off time	9:00 CET
Distribution policy	Accumulating

Investment manager	Bellevue Asset Management AG
Custodian	RBC Investor Services, Luxembourg
Launch date	31.05.2017
Fiscal year end	30.06.
Benchmark	MSCI Emerging Markets HC NetTR

ISIN code	LU1585228882
Valor	36153236
Bloomberg	BBAEMIE LX
WKN	A2DPAY

Management fee	0.90%
Performance fee	10% above Benchmark*
Subscription fee	up to 5%
Min. investment	n.a.

Legal entity	Luxembourg UCITS V SICAV
Countries of distribution	AT, CH, DE, ES, LU
EU SFDR 2019/2088	Article 8

### Key figures


Beta	0.78
Correlation	0.9
Volatility	19.5%

Tracking Error	9.81
Active Share	53.91

Sharpe Ratio	0.63
Information Ratio	0.27
Jensen's Alpha	5.04

Source: Bellevue Asset Management, 31.08.2021;  
Calculation over 3 years.  
\* With high watermark

### Indexed performance since launch




### Cumulated & annualized performance

	Cumulated						Annualized			
	1 month	YTD	1 year	3 years	5 years	since launch	1 year	3 years	5 years	since launch
I EUR	-3.4%	-1.3%	6.0%	38.4%	n.a.	65.1%	6.0%	11.4%	n.a.	12.5%
BM	-0.4%	0.8%	10.7%	21.5%	n.a.	44.1%	10.7%	6.7%	n.a.	9.0%
MSCI EM	3.1%	6.5%	22.5%	30.2%	n.a.	37.2%	22.5%	9.2%	n.a.	7.7%

### Annual performance

	2016	2017	2018	2019	2020	YTD
I EUR	n.a.	n.a.	-9.1%	18.1%	37.9%	-1.3%
BM	n.a.	n.a.	-17.0%	5.7%	40.4%	0.8%
MSCI EM	n.a.	n.a.	-10.3%	20.8%	8.7%	6.5%

### Rolling 12-month performance



Source: Bellevue Asset Management, 31.08.2021; all figures in EUR %, total return / BVI-methodology  
Past performance is not a reliable indicator of future results and can be misleading. As the subfund is denominated in a currency that may differ than an investor's base currency, changes in the rate of exchange may have an adverse effect on prices and incomes. Performance is shown net of fees and expenses for the relevant share class over the reference period. All performance figures reflect the reinvestment of dividends and do not take into account the commissions and costs incurred on the issue and redemption of shares, if any. Individual costs are not taken into account and would have a negative impact on the performance. With an investment amount of EUR 1,000 over an investment period of five years, the investment result in the first year would be reduced by the front-end load of up to EUR 50 (5%) as well as by additional individual custody charges. In subsequent years, the investment result would also be reduced by the individual custody account costs incurred. The reference benchmark of this class is used for performance comparison purposes only (dividend reinvested). No benchmark is directly identical to a subfund, thus the performance of a benchmark is not a reliable indicator of future performance of the subfund it is compared to. There can be no assurance that a return will be achieved or that a substantial loss of capital will not be incurred.

### Top 10 positions

Richter Gedeon		5.1%
Wuxi Biologics		5.0%
Celltrion		4.1%
Innovent Biologics		4.0%
Wuxi Apptec		4.0%
Samsung Biologics		3.9%
Aspen Pharmacare		3.9%
Sun Pharmaceutical		3.8%
Rede D'Or		3.5%
Cipla		3.5%

Total top 10 positions	40.8%
Total positions	39

### Geographic breakdown

China		48.9%
India		15.4%
South Korea		10.3%
Brazil		8.1%
Hungary		5.1%
South Africa		3.9%
Jordan		2.8%
Malaysia		2.3%
Cash		3.2%

### Market cap breakdown

2 - 5 bn		8.2%
5 - 15 bn		40.9%
15 - 20 bn		9.4%
> 20 bn		38.3%
Others		3.2%

### Market review

TINA (there is no alternative to equities) is still the driving force on stock markets. Global equity markets as tracked by the MSCI World Index advanced another 2.5% in USD. In addition to expansionary central bank policies, markets were buoyed by the very pleasing quarterly results. Uncertainty triggered by further regulatory action from the central Chinese government clouded the overall positive sentiment only briefly. Emerging markets therefore also ended the month in positive territory, with a gain of 2.6%. Fears that future intervention by China's Communist Party could target the healthcare sector led to some selling pressure. Consequently, these stocks retreated 0.8% over the month and were about 2.7% lower at the end of August than at the beginning of the year.

Investor worries related to political uncertainty in China have injected considerable volatility into the country's healthcare stocks. It is important to note that the healthcare sector is already highly regulated. Over the past decade, Chinese healthcare companies have become accustomed to complying with strict regulations in all areas of their operations (R&D, regulatory approval processes, marketing, commercialization, pricing, etc.). Access to high-quality healthcare products and services that ordinary citizens can afford is one of the Chinese government's top priorities, especially against the backdrop of a rapidly aging population.

Most of the Chinese stocks in the portfolio published excellent half-year results. Wuxi Biologics reported first-half sales growth of 127% y-o-y. It added 79 new molecules to its R&D pipeline and is now working on more than 400 integrated projects. Wuxi was able to win 12 new molecules from competing suppliers. Shangdong Weigao reported first-half sales growth of more than 19%. Biotech company Innovent published strong growth numbers for its leading PD-1 inhibitor Tyvyt despite increasing competition in the wake of last year's NRDL negotiations. Innovent now has 2 000 sales representatives covering more than 4 700 hospitals in China.

Apollo Hospitals, an Indian healthcare services provider, reported an impressive 18% increase in revenues and EBITDA for the second quarter, clearly topping market expectations. COVID-19-related services such as vaccines and diagnostic tests made a particularly surprising contribution to this growth. Its shares were marked sharply higher on the day of the earnings announcement and we realized profits on this strength.

In August positions were opened in Weigao, Mindray, Cansino Biologics and Joinn Laboratories and existing positions in Wuxi Biologics, Hygeia, Innovent and Zhifei were increased. Akeso, Venus Medtech and Lupin are no longer in the portfolio and positions in ZaiLab and Glenmark were trimmed.

### Positioning & outlook

The fastest growing countries in the world can be found in emerging markets and they contain more than half of the world's population. Asian emerging markets are also forecast to account for more than 50% of global GDP by 2050. It is known that the economic growth model of countries shifts from manufacturing to the services sector as household incomes rise. A growing middle class fuels demand for modern medicine. Healthcare ranks increasingly high on their wish list. Billions are being invested in infrastructure, technology and research to modernize the healthcare systems in emerging market countries. This is giving a broader access to better healthcare. Meanwhile rapid population aging is also increasing demand for healthcare. In 30 years' time there will be 400 to 500 million people over 60 in China alone, and they will have a growing need for modern health services and medicines.

Outside Asia, Brazil's rapidly expanding private-sector healthcare market offers a range of interesting investment opportunities. The quality and long waiting times of the country's public health system are no longer acceptable to many higher-income Brazilian households and they are increasingly embracing these new services offered by private-sector healthcare providers. Hospital chains embedded in a fully-integrated ecosystem are but one example of the beneficiaries of this structural change. The fund serves as a defensive vehicle for capturing the above-average growth potential emerging markets offer. It invests in the entire healthcare system value chain, from hospital chains, drug developers and device manufacturers to medical research specialists and digital health companies.

Source: Bellevue Asset Management, 31.08.2021;

For illustrative purposes only. Holdings and allocations are subject to change. Any reference to a specific company or security does not constitute a recommendation to buy, sell, hold or directly invest in the company or securities. Where the subfund is denominated in a currency other than an investor's base currency, changes in the rate of exchange may have an adverse effect on price and income.

### Risk and return profile

The fund's objective is to generate an attractive return over a long-term horizon. It is therefore particularly suited to investors with an investment horizon of at least 5 years who want to diversify their portfolio with selective exposure to the healthcare sector in Emerging Markets and who are willing to accept the risks typically associated with stocks in this sector



This fund is assigned to this category, as its share price fluctuates severely and both the risk of loss and the opportunities for profit can therefore be high. The calculation of the risk and earnings profile is based on simulated/historical data, which cannot be used as a reliable indication of the future risk profile. The classification of the fund may change in future and does not constitute a guarantee. Even a fund classed in category 1 does not constitute a completely risk-free investment. There can be no guarantee that a return will be achieved or that a substantial loss of capital will not be incurred. The overall risk exposure may have a strong impact on any return achieved by the fund or subfund. For further information please refer to the fund prospectus or KIID.

### Liquidity risk

The fund may invest some of its assets in financial instruments that may in certain circumstances reach a relatively low level of liquidity, which can have an impact on the fund's liquidity.

### Risk arising from the user of derivatives

The fund may conclude derivatives transactions. This increases opportunities, but also involves an increased risk of loss.

### Currency risks

The fund may invest in assets denominated in a foreign currency. Changes in the rate of exchange may have an adverse effect on prices and incomes.

### Operational risks and custody risks

The fund is subject to risks due to operational or human errors, which can arise at the investment company, the custodian bank, a custodian or other third parties.

### Target market

The fund is suitable for retail and professional investors in Austria, Germany, Luxembourg, Spain and Switzerland.

### Chances

- Access to defensive growth – emerging countries are facing aging populations and changing lifestyles.
- Development of healthcare infrastructure combined with a growing middle class is an additional growth driver.
- High growth potential of Emerging Markets.
- Attractive valuations compared with the projected medium to long-term growth.
- BB Adamant Team – top-performing pioneer in the management of healthcare portfolios in Emerging Markets.

### Inherent risks

- The fund invests in equities. Equities are subject to price fluctuations and so are also exposed to the risk of price losses.
- Investing in Emerging Markets entails the additional risk of political and social instability.
- The fund invests in foreign currencies, which means a corresponding degree of currency risk against the reference currency.
- The subfund may invest in China A equities. This entails the risk of supervisory changes, volume caps and operating restrictions which may lead to a higher counterparty risk.
- The fund may invest a proportion of its assets in financial instruments that might under certain circumstances have a relatively low level of liquidity, which can in turn affect the fund's liquidity.

You can find a detailed presentation of the risks faced by this fund in the "Special Investment Risks" section of the sales prospectus.

### Management Team



**Oliver Kubli, CFA**  
Portfolio Manager  
since inception of the fund



**Remo Krauer, CIIA**  
Portfolio Manager of  
the fund since 2018



**Dr. Cyrill Zimmermann**  
Portfolio Manager  
since inception of the fund

### Awards



### Sustainability Profile – ESG

<b>Norms-based exclusions:</b>	<input checked="" type="checkbox"/> Compliance UNGC, HR, ILO	<input checked="" type="checkbox"/> Controversial weapons
<b>ESG Risk Analysis:</b>	<input checked="" type="checkbox"/> ESG Integration	<input type="checkbox"/> Best-in-Class
<b>Stewardship:</b>	<input checked="" type="checkbox"/> Engagement	<input checked="" type="checkbox"/> Proxy Voting

<b>CO2 intensity (t CO2/mn USD sales):</b>	51.5 t (low)	MSCI ESG coverage: 89%
<b>MSCI ESG Rating (AAA - CCC):</b>	BB	MSCI ESG coverage: 86%
<b>EU SFDR 2019/2088 product category:</b>	Article 8	

Based on portfolio data as per 30.06.2021 (quarterly updates) – ESG data base on MSCI ESG Research and are for information purposes only; compliance with global norms according to the principles of UN Global Compact (UNGC), UN Guiding Principles for Business and Human Rights (HR) and standards of International Labor Organisation (ILO); no involvement in controversial weapons; ESG Integration: Sustainability risks are considered while performing stock research and portfolio construction; Best-in-class: systematic exclusion of "ESG laggards"; MSCI ESG Rating ranges from "leaders" (AAA-AA), "average" (A, BBB, BB) to "laggards" (B, CCC). Note: in certain cases the ESG rating methodology may lead to a systematic discrimination of companies or industries, the manager may have good reasons to invest in supposed "laggards". The CO2 intensity expresses MSCI ESG Research's estimate of GHG emissions measured in tons of CO2 per USD 1 million sales; for further information c.f. [www.bellevue.ch/en/corporate-information/sustainability](http://www.bellevue.ch/en/corporate-information/sustainability)

## *Important information*

This marketing communication relates to Bellevue Funds (Lux) (hereinafter the “Fund”), an investment company with variable capital “société à capital variable” (SICAV) under the current version of the Law of the Grand Duchy of Luxembourg of 10 August 1915 on commercial companies (“Law of 1915”) and is authorized under Part I of the Law of 17 December 2010 relating to undertakings for collective investment (“Law of 2010”) as an undertaking for collective investment (UCITS). BB Adamant Emerging Markets Healthcare is a subfund of Bellevue Funds (Lux).

This marketing communication is issued by Bellevue Asset Management AG, which is an authorized asset manager subject to the supervision of the Swiss Financial Market Supervisory Authority (FINMA) and acts as an Investment Manager of the Fund. The Prospectus, statutes, the annual and half-yearly report, the share prices and further information about the Fund can be obtained free of charge in English and German from the management company of the Fund, Bellevue Asset Management AG, Seestrasse 16, CH-8700 Küsnacht, from the representative, paying, facilities and information agents mentioned below or online at [www.bellevue.ch](http://www.bellevue.ch). The Key Investor Information documents are available free of charge in the languages of the countries of distribution at [www.fundinfo.com](http://www.fundinfo.com).

This document is neither directed to, nor intended for distribution or use by, any person or entity who is a citizen or resident of any locality, state, country or jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation. It is particularly not intended for US persons, as defined under Regulation S of the U.S. Securities Act of 1933, as amended. The information and data presented in this document are not to be considered as an offer to buy, sell or subscribe to any securities or financial instruments. The information, opinions and estimates contained in this document reflect a judgment at the original date of release and are subject to change without notice. This information pays no regard to the specific or future investment objectives, financial or tax situation or particular needs of any specific recipient and in particular tax treatment depends on individual circumstances and may be subject to change. This document is not to be relied upon in substitution for the exercise of independent judgment. Before making any investment decision, investors are recommended to ascertain if this investment is suitable for them in the light of their financial knowledge and experience, investment goals and financial situation, or to obtain specific advice from an industry professional. The details and opinions contained in this document are not to be considered as recommendation or investment advice. Every investment involves risk, especially with regard to fluctuations in value and return, and investors’ capital may be at risk. If the currency of a financial product is different from your reference currency, the return can increase or decrease as a result of currency fluctuations. Past performance is no indicator for the current or future performance. The performance data are calculated without taking account of commissions and costs that result from subscriptions and redemptions. Commissions and costs have a negative impact on performance. For more information about the associated costs, please refer to the related costs and fees section of the prospectus. Any benchmarks/indices cited herein are provided for information purposes only. No benchmark/index is directly comparable to the investment objectives, strategy or universe of the subfund. The performance of a benchmark shall not be indicative of past or future performance of the subfund. Financial transactions should only be undertaken after having carefully studied the current valid prospectus and are only valid on the basis of the latest version of the prospectus and available annual and half-yearly reports. Please take note of the risk factors.

## **Countries of distribution and local representatives**

The Bellevue Funds (Lux) is registered and admitted for public distribution in AT, DE, LU, ES and CH.

**Austria:** Paying and information agent: ERSTE BANK der oesterreichischen Sparkassen AG, Am Belvedere 1, A-1100 Vienna

**Germany:** Information agent: ACOLIN Europe GmbH, Reichenaustrasse 11a-c, D-78467 Konstanz

**Spain:** Representative: atl Capital, Calle de Montalbán 9, ES-28014 Madrid - CNMV under the number 938

**Switzerland:** The Bellevue Funds (Lux) SICAV is registered for public offering and distribution in Switzerland with the Swiss Financial Market Supervisory Authority. Representative agent in Switzerland: Waystone Fund Services (Switzerland) SA, Avenue Villamont 17, CH-1005 Lausanne. Paying agent in Switzerland: DZ PRIVATBANK (Schweiz) AG, Münsterhof 12, P.O. Box, CH-8022 Zürich. You can obtain the sales prospectus, Key Investor Information Document (“KIID”), statutes and the current annual and half-yearly reports, the current share prices and further information about the fund free of charge in German from the management company Bellevue Asset Management AG, Seestrasse 16, CH-8700 Küsnacht, the representative agent in Switzerland or online at [www.bellevue.ch](http://www.bellevue.ch). In respect of the units distributed in or from Switzerland, the place of performance and jurisdiction is at the registered office of the representative agent.

Copyright©2021 Bellevue Asset Management, Inc. All rights reserved.

Citywire information is proprietary and confidential to Citywire Financial Publishers Ltd (“Citywire”), may not be copied and Citywire excludes any liability arising out of its use.

© 2021 MSCI ESG Research LLC. Reproduced by permission. Although Bellevue Asset Management information providers, including without limitation, MSCI ESG Research LLC and its affiliates (the “ESG Parties”), obtain information from sources they consider reliable, none of the ESG Parties warrants or guarantees the originality, accuracy and/or completeness of any data herein. None of the ESG Parties makes any express or implied warranties of any kind, and the ESG Parties hereby expressly disclaim all warranties of merchantability and fitness for a particular purpose, with respect to any data herein. None of the ESG Parties shall have any liability for any errors or omissions in connection with any data herein. Further, without limiting any of the foregoing, in no event shall any of the ESG Parties have any liability for any direct, indirect, special, punitive, consequential or any other damages (including lost profits) even if notified of the possibility of such damages.

The most important terms are explained in the glossary at [www.bellevue.ch/en/glossary](http://www.bellevue.ch/en/glossary)